Fresenius’ Frenova launches clinical trial accelerator

Dialysis giant Fresenius‘s (NYSE:FMS) renal research branch Frenova said today it launched a renal research accelerator, titled F1RST Up, through an alliance of physician investigators in the nephrology research field. The accelerator aims to boost study startup through the elimination of administrative and contracting burdens that plague clinical trials, and are often responsible for delays, the Waltham, Mass.-based company said. “F1RST Up was conceived and organized with value for all of our stakeholders in mind. We worked very closely with our F1RST Up physician partners and clients to both identify and magnify the value drivers for our sites, sponsors and patients. F1RST Up works because it takes a no-nonsense approach to moving immediately from study award to study start, and that is the foremost value driver for sponsors,” Frenova GM Kurt Mussina said in prepared remarks. The F1RST Up program is made up of a group of clinical research sites in Frenova’s investigative network, which focus on vascular access and care, cardio-renal conditions, chronic kidney disease, end stage renal disease, cardiovascular disease, rare and infectious diseases and transplants. Frenova was relaunched in March, 2014. Formerly known known as the “Clinical Studies Group at FMCNA,” Frenova has been around since 2001 and provides support for clinical trials specific to kidney disease and related conditions. Frenova is the only Phase I-V clinical partner dedi...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Clinical Trials Frenova Renal Research Fresenius Medical Care Source Type: news